TOP 100 MEDICAL SITES
| |||
|
| |||
| |||
|
| |||
| Stock Alert for Cord Blood America Inc. Issued by MicroStockProfit (GlobeNewswire) DALLAS -- MicroStockProfit.com announces an investment report featuring Cord Blood America Inc. . The report includes financial, comparative and investment analyses, and industry information you need to know to make an educated investment decision. us.rd.yahoo.com |
Aetna Contracts CVS to Run PBM Aetna is contracting out its pharmacy-benefit business to CVS Caremark in a 12-year deal, and the health insurer posted a 42% increase in profit. online.wsj.com |
Compugen Goes the Extra Mile in Drug Discovery Prohost Biotech submits:With the evolution of the genomic and proteomic technologies, we highly regard and appreciate the firms that have invested in these technology towards breakthrough discoveries that are used in a therapeutic progress towards healing chronic and deadly diseases. One of these firms has offered us more than hints about what it can accomplish through its thoroughly developed technologies. The firm in question is Compugen (CGEN) and is still small as measured by its market cap, but we see it as a future giant based on its achievements. Using its LEADS Platform and other proprietary algorithms and technologies, Compugen was capable of predicting in silico the existence of novel members of the B7/CD28 family of co-stimulatory proteins, and discovering an extracellular region of the predicted (previously unknown) membrane protein in the B7/CD28 family. B7/CD28 co-stimulation protein family is of extreme importance in immune regulation. Compugen’s predictive capability and experimental validation of a previously unknown member of this important protein family represents a major advancement in therapeutic discovery from being totally based on experimentation to originating from in silico prediction and selection new capabilities. With the discovery of the new extracelluar region membrane protein in the B7/CD28 family, Compugen has walked extra steps towards developing a product, CGEN-15001, as a novel soluble recombinant fusion protein that corresponds to the extracellular region of the discovered parent protein. Compugen is patenting both the parent protein, which potentially has other medical uses such as a target for antibody therapeutics, and its CGEN-15001 molecules. Complete Story » seekingalpha.com |
What's Happening to Your Health Plan The health-care overhaul may be driving prices up, forcing some employers to raise costs or limit choices. We explain how to play the mother of all open-enrollment seasons. online.wsj.com |
Savient Angers Investors by Flying Solo EP Vantage submits:Savient Pharmaceuticals (SVNT) does not seem to have learned from past mistakes. The New Jersey biotech raised the stakes on its last failed attempt to find a big pharma marketing partner for its gout therapy Krystexxa by seeking a trade sale, and lost close to half its value Monday after it announced it will now fly solo (Savient's broken promises cause share woe, September 30, 2008).The decision puts the company in the unenviable position of having to draw heavily on its $89m cash pile to build a commercial infrastructure, something it always hoped would be handled by a partner or buyer. Commercializing the drug itself is not an unattainable goal, as Krystexxa (pegloticase) is a specialty product for patients who fail on first-line treatments. However, with widely varying estimates on the commercial prospects of the product, it is not at all clear what the payoff will be in the long term (Savient needs to deliver partner sooner rather than later, September 15, 2010).Complete Story » seekingalpha.com |